Efficacy and safety of immunotherapy in real-world patients with advanced non-small cell lung cancer

This study reports the practical experience of ICIs in the treatment of NSCLC in China by analyzing the efficacy and safety of real-world advanced NSCLC treated with ICIs. The results were generally consistent with those of clinical trials, and the factors with the greatest impact on the efficacy of ICIs were ECOG PS, clinical stage, and PNI. Therefore, physicians can predict the future benefit of immunotherapy for NSCLC based on clinical prognostic indicators and make individualized treatment choices.